Wallaby Medical Holding, Inc. (referred to as "Wallaby Medical" below) was established in December 2015, with a focus on developing innovative, breakthrough, and clinically validated technologies and solutions for the treatment of neurovascular diseases.

In April 2022, Wallaby Medical successfully acquired phenox GmbH (hereinafter referred to as "phenox"), a leading global neurointerventional company based in Germany. Following the acquisition, Wallaby Medical holds a complete and globally competitive portfolio of neurointerventional products, with 5 R&D centers, 3 production bases, over 700 employees worldwide.

The vision of the company is to "save more lives impacted by stroke." Since Wallaby Medical is a comprehensive multinational medical technology company with an extensive global business presence, its products are sold in more than 60 countries and regions, including China, the United States, major European economies, and Japan. The Avenir^® Coil System has been approved by the United States, the European Union, China and Japan. The Esperance™ Aspiration Catheter,  Esperance™ Distal Access Catheter, Pilote™ Distal Access Catheter and pNOVUS™ 17 Microcatheter have obtained approval in China, and the Esperance™ Aspiration Catheter has been approved in the United States. The pRESET^® Thrombectomy Device  has been approved for marketing in the United States and Europe. p64 and p48 Flow Modulation Device have also been approved in Europe. Other innovative medical devices already available in the market for the treatment of stroke include support coil stents, bifurcation aneurysm embolization devices and vascular access products.